Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Newsfilter· 2024-08-01 20:30
Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet need for patients with relapsed or refractory PTCL, an indication with poor overall outcomes and no approved drugs based on randomized trials BURLINGAME, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and ...
Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System
Newsfilter· 2024-08-01 20:30
BRAINTREE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced it has entered into an agreement with Emory University, which will allow the parties to evaluate and explore the potential for a future collaboration in connection with autonomous robotics in endovascular procedures. Under the terms of the agreement, Emory University will assume the responsibility of exploring the feasibility of integrating the LIBERTY® Endovascular Robotic Surgical System with an imagin ...
Carver Bancorp, Inc. Interim CEO Craig C. MacKay Comments on the Bank's 2024 Fiscal Year-End Performance
Prnewswire· 2024-08-01 20:30
NEW YORK, Aug. 1, 2024 /PRNewswire/ -- Carver Bancorp, Inc. (Nasdaq: CARV), the holding company for Carver Federal Savings Bank, released a letter from its Interim CEO Craig C. MacKay on the Bank's 2024 fiscal year-end performance: Dear Carver Shareholders: We remain optimistic about the Bank's future - Craig C. MacKay Post this Carver Bancorp, Inc. Interim CEO Craig C. MacKay Comments on the Bank's 2024 Fiscal Year-End Performance Carver Bancorp, Inc. ("Carver") reduced its net loss by 32% to $3.0 million ...
PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature
Newsfilter· 2024-08-01 20:30
TEL AVIV, Israel, Aug. 01, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announces a major advancement in the development of its lead asset, PRF-110. The Company's new highly scalable manufacturing process, for which it recently filed a new patent, has enabled PRF-110 to achieve full product stability for 18 months at room temperature. This stability study is ...
Cellebrite Appoints Renowned Cybersecurity Expert Sigalit Shavit as Chief Information Officer
Newsfilter· 2024-08-01 20:30
文章核心观点 - 赛莱布莱特公司任命Sigalit Shavit为首席信息官(CIO),她将在公司领导团队中发挥关键作用,帮助公司加强创新能力和客户支持 [1][2][3][4] - Shavit拥有30多年的信息技术和安全经验,曾在FedEx Express、CyberArk等公司担任过CIO和COO等高级职位 [5] - Shavit将专注于确保赛莱布莱特的信息技术和安全组织能够持续满足业务需求,应对不断变化的网络威胁,并利用人工智能加速创新 [3][4][6] 公司概况 - 赛莱布莱特是一家为公共和私营部门提供数字调查解决方案的全球领导者 [7] - 公司的使命是帮助客户保护和拯救生命、加速司法正义和维护社区隐私 [7] - 赛莱布莱特的数字调查平台和解决方案可以帮助客户更高效地收集、审查、分析和管理合法调查中的数据 [7] 新任CIO简介 - Sigalit Shavit是一位经验丰富的信息技术和安全专家,曾在多家知名企业担任过高级管理职位 [5] - 在CyberArk任职期间,她在公司向企业级云/SaaS转型中发挥了关键作用 [5] - Shavit对于赛莱布莱特的使命感到非常兴奋,将致力于制定清晰的现代数字战略和解决方案,提高效率并加速创新 [6]
Intelligent Bio Solutions Partners with CenExel to Conduct Clinical Study as Part of FDA 510(k) Pathway
Newsfilter· 2024-08-01 20:30
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its partnership with CenExel, a nationwide clinical research site network, to perform a method comparison clinical study as part of the Company's FDA 510(k) clinical study plan. The Company's method comparison study will recruit 135 healthy adult subjects across three sites under an IRB- ...
Entera's EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting - Key SABRE Update Also Expected
Newsfilter· 2024-08-01 20:30
JERUSALEM, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that new comparative pharmacological data for its investigational agent EB613 vs. Forteo® was selected for presentation at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting which will be held on September 27-30, 2024 in Toronto, ON, Canada. EB613 is being developed as the first o ...
Inuvo to Host Second Quarter 2024 Financial Results Conference Call on Thursday, August 8th at 4:15 P.M. ET
Newsfilter· 2024-08-01 20:30
会议相关 - 公司Inuvo将于2024年8月8日下午4点15分（东部时间）召开电话会议讨论截至2024年6月30日的第二季度财报并提供业务更新 [1] - 会议免费拨入号码为1 - 800 - 717 - 1738国际拨入号码为1 - 646 - 307 - 1865会议ID为1174796网络直播链接为HERE [2] - 电话重播将持续到2024年8月22日国内重播拨入1 - 844 - 512 - 2921国际重播拨入1 - 412 - 317 - 6671按提示输入1174796及号后输入姓名公司和电话号码即可开始重播 [2] 公司相关 - 公司Inuvo是人工智能广告领域的市场领导者其IntentKey AI解决方案是首创的专有和专利技术能够识别并响应消费者对产品服务或品牌感兴趣的原因而非消费者是谁 [3] - 可访问www.inuvo.com了解更多公司信息 [3] 公司联系相关 - 公司财务官为Wally Ruiz电话(501)205 - 8397邮箱wallace.ruiz@inuvo.com [5] - 投资者关系相关人员为David Waldman / Natalya Rudman联系公司为Crescendo Communications, LLC电话(212)671 - 1020邮箱inuv@crescendo - ir.com [5]
Keiretsu Forum Mid-Atlantic, South-East and Texas Announces Latest Liquidity Event with SWIR Vision Systems
Newsfilter· 2024-08-01 20:20
PHILADELPHIA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Keiretsu Forum Mid-Atlantic, South-East, and Texas regions proudly announce the latest liquidity event for investor members. SWIR Vision Systems, an early-stage company specializing in short-wave infrared (SWIR) technology, has been acquired by onsemi. The move was announced in early July by onsemi. This acquisition marks a significant milestone for Keiretsu Forum members and the investment community. SWIR Vision Systems joined the Keiretsu Forum portfolio aft ...
Syntec Optics (Nasdaq: OPTX) Launches Production of New Disposable Optics for Characterization of Biomolecules and Nanoparticles
Newsfilter· 2024-08-01 20:18
ROCHESTER, NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Syntec Optics, a leading provider of mission-critical optics for scientific and technical instruments and equipment OEMs in diverse defense, biomedical, communications, and consumer end-markets, announced today that it has launched the production of biomolecules and nanoparticles characterization optics used in direct light scattering instruments for biopharma technologists. Syntec's new disposable optics enable fast measurements for low-volume requirem ...